EVG Evgen Pharma

EQS-News: Evgen Pharma 'cash runway in pretty good shape'

EQS-News: Evgen Pharma PLC
Evgen Pharma 'cash runway in pretty good shape'

12.12.2022 / 12:53 CET/CEST
The issuer is solely responsible for the content of this announcement.

Contact Details

Proactive

Proactive UK Ltd

3


News Source: News Direct

12.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com
Language: English
Company: Evgen Pharma PLC
United States
ISIN: GB00BSVYN304
EQS News ID: 1510673

 
End of News EQS News Service

1510673  12.12.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1510673&application_name=news&site_id=research_pool
EN
12/12/2022

Underlying

EVGEvgen Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Evgen Pharma

Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf | R&D Day confirms potential

TheraCryf held a Research and Development Day (R&DD) concentrating on the progress of SFX-01, its lead clinical asset in the study relating to glioblastoma at Erasmus University in the Netherlands, and on the two new candidates acquired in the Chronos acquisition. The Erasmus study is demonstrating very encouraging initial results with the drug on track for trial in humans by early 2026. The R&DD explained the differentiated potential in the Orexin and dopamine transporter (DAT) inhibitor progr...

06/14/24 June 14, 2024 1 EN
Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf | FY24 results - in line; trebled shots on target

TheraCryf reported a net loss for FY24 of £3.1m together with cash and net cash of £2.0m, in line with our forecasts. Post year end, the company raised £0.8m (net) in conjunction with its acquisition of Chronos Therapeutics (Chronos), which trebled its drug development pipeline. The company has a financial runway through towards the end of FY26. Despite its advantages, TheraCryf trades on a fraction of the rating of peers with similar characteristics and has multiple prospective newsflow events...

05/28/24 May 28, 2024 1 EN
Colin Smith
  • Colin Smith
EVG EVGEN PHARMA

TheraCryf: Initiation - Strong Healing

TheraCryf is a clinical stage drug development company focused on commercialising its proprietary formulation of sulforaphane, SFX-01, and two novel drug candidates acquired in the recent Chronos transaction. The primary targets for SFX-01 are cancer and neurodevelopmental disorders while TheraCryf's new orexin and DAT programmes, extend the company's reach into neuropsychiatric drugs, currently a very active area for acquisitions and partnering. Potential target markets total in the billions of...

05/20/24 May 20, 2024 1 EN
Emily Liu
  • Emily Liu
HAYD Haydale Graphen...
KIBO KIBO ENERGY ... (+7)

Hybridan Small Cap Feast 26-10-2023

Dish of the day Joiners: No joiners today. Leavers: No leavers today. What’s cooking in the IPO kitchen?** Announced ITF 2 October: Adsure Services, the holding company for TIAA Limited, a specialist business assurance provider operating across the Housing, Healthcare, Government, Education, Charities, and other sectors in the UK, intends to join the Access Segment of the AQSE Growth Market. Admission expected on 30 October. Tekcapital announced intention to spin off and IPO on 2 October: MicroS...

HAYD HAYDALE GRAPHENE INDUSTRIES
KIBO KIBO ENERGY
HUM HUMMINGBIRD RESOURCES
EVG EVGEN PHARMA
CUSN CORNISH METALS
POLB POOLBEG PHARMA PLC
CTL CLEANTECH LITHIUM PLC
10/26/23 October 26, 2023 1 EN
TRX Tissue Regenix ...
GAMA Gamma Communica... ... (+7)

Hybridan Small Cap Feast - 05 Sep 23

5th September 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obj...

TRX TISSUE REGENIX GROUP
GAMA GAMMA COMMUNICATIONS
JSG JOHNSON SERVICE GROUP PLC
MBH MICHELMERSH BRICK HOLDINGS PLC
EVG EVGEN PHARMA
SBTX SKINBIOTHERAPEUTICS
TXG 10X GENOMICS INC CLASS A
09/05/23 September 5, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch